Little Green Pharma Ltd (ASX: LGP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Little Green Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Little Green Pharma Ltd (ASX: LGP)
Latest News
Share Market News
Why the Little Green Pharma (ASX:LGP) share price climbed 5% today
Share Market News
The Little Green Pharma (ASX:LGP) share price dived 16% after this announcement
Share Market News
Why the Little Green Pharma (ASX:LGP) share price will be on watch today
Share Market News
Little Green Pharma (ASX:LGP) share price whiskers near all-time high
Share Market News
What does the Biden administration mean for ASX shares?
Share Market News
Little Green Pharma (ASX:LGP) share price leaps 10% on this ASX announcement
LGP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Little Green Pharma Ltd
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets.
LGP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $0.12 | $-0.02 | -14.81% | 564,836 | $0.15 | $0.15 | $0.12 |
31 Oct 2024 | $0.14 | $0.00 | 0.00% | 144,853 | $0.14 | $0.14 | $0.13 |
30 Oct 2024 | $0.14 | $-0.01 | -7.14% | 191,799 | $0.14 | $0.15 | $0.14 |
29 Oct 2024 | $0.14 | $0.00 | 0.00% | 553,676 | $0.14 | $0.16 | $0.14 |
28 Oct 2024 | $0.14 | $0.00 | 0.00% | 326,193 | $0.15 | $0.16 | $0.14 |
25 Oct 2024 | $0.15 | $-0.01 | -6.45% | 1,391,231 | $0.16 | $0.16 | $0.15 |
24 Oct 2024 | $0.16 | $0.01 | 6.90% | 345,217 | $0.15 | $0.16 | $0.15 |
23 Oct 2024 | $0.15 | $-0.01 | -6.45% | 25,059,808 | $0.16 | $0.16 | $0.15 |
22 Oct 2024 | $0.16 | $-0.01 | -6.25% | 491,688 | $0.16 | $0.17 | $0.16 |
21 Oct 2024 | $0.16 | $0.01 | 6.45% | 1,103,362 | $0.16 | $0.16 | $0.14 |
18 Oct 2024 | $0.16 | $0.04 | 34.78% | 2,382,821 | $0.12 | $0.17 | $0.12 |
17 Oct 2024 | $0.12 | $0.03 | 34.09% | 1,315,247 | $0.09 | $0.13 | $0.09 |
16 Oct 2024 | $0.09 | $0.00 | 0.00% | 148,699 | $0.09 | $0.09 | $0.09 |
15 Oct 2024 | $0.09 | $0.00 | 0.00% | 147,880 | $0.09 | $0.09 | $0.09 |
14 Oct 2024 | $0.09 | $0.01 | 11.76% | 370,039 | $0.09 | $0.09 | $0.09 |
11 Oct 2024 | $0.09 | $0.00 | 0.00% | 172,324 | $0.09 | $0.09 | $0.09 |
10 Oct 2024 | $0.09 | $0.00 | 0.00% | 85,680 | $0.09 | $0.09 | $0.09 |
09 Oct 2024 | $0.08 | $0.00 | 0.00% | 39,194 | $0.09 | $0.09 | $0.08 |
08 Oct 2024 | $0.09 | $0.00 | 0.00% | 23,340 | $0.09 | $0.09 | $0.08 |
07 Oct 2024 | $0.09 | $0.01 | 12.20% | 38,297 | $0.08 | $0.09 | $0.08 |
04 Oct 2024 | $0.08 | $0.00 | 0.00% | 110,817 | $0.09 | $0.09 | $0.08 |
03 Oct 2024 | $0.08 | $0.00 | 0.00% | 42,699 | $0.08 | $0.09 | $0.08 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Sep 2024 | Angus Caithness | Issued | 2,000,000 | $184,000 |
Issue of options. As per announcement on 06-09-2024
|
02 Sep 2024 | Fleta Solomon | Issued | 1,200,000 | $110,400 |
Issue of options. As per announcement on 06-09-2024
|
15 Apr 2024 | Fleta Solomon | Exercise | 36,000 | $5,040 |
Conversion of securities. 4,000,000 Rights
|
15 Apr 2024 | Fleta Solomon | Issued | 36,000 | $5,040 |
Conversion of securities.
|
15 Apr 2024 | Angus Caithness | Issued | 32,000 | $4,480 |
Conversion of securities. Typo error
|
15 Apr 2024 | Angus Caithness | Exercise | 32,000 | $4,480 |
Conversion of securities. 4,000,000 Rights, Typo error
|
03 Apr 2024 | Neale Fong | Exercise | 35,000 | $5,250 |
Conversion of securities. 105,000 Retention Share Rights
|
03 Apr 2024 | Neale Fong | Buy | 35,000 | $5,250 |
Conversion of securities.
|
03 Apr 2024 | Michael Lynch-Bell | Buy | 70,000 | $10,500 |
Conversion of securities.
|
03 Apr 2024 | Michael Lynch-Bell | Exercise | 70,000 | $10,500 |
Conversion of securities. 210,000 Retention Share Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Neale William Fong | Non-Executive Director | Nov 2018 |
Dr Fong has over 36 years in leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organisations. Neale is currently CEO of Bethesda Health Care and formerly was Director General of the West Australian Department of Health. Neale is also Chair of the Risk Committee.
|
Mr Angus McDougall Caithness | Executive Director | Feb 2018 |
Mr Caithness is a corporate finance executive and consultant in Australia and international markets. Angus has ASX experience as a Company Secretary for the IPO of Haranga Resources (ASX:HAR). Following these roles, Angus acted as CFO of Tavan Tolgoi, the owner of coking coal deposit looking at a US$10 billion dual listing in London and Hong Kong prior to the change in the Mongolian government. Angus was previously an Executive Director at Ernst & Young in London and Australia specialising in initial public offerings of large cap mining companies.
|
Ms Fleta Jennifer Solomon | Chief Executive OfficerManaging Director | May 2017 |
Ms Solomon was a founder of Little Green Pharma and has grown the company from a medicinal cannabis startup to an industry leading medicinal cannabis brand in Australia and overseas. Fleta has 20 years' experience in corporate and consumer health markets.
|
Mr Michael David Lynch-Bell | Non-Executive ChairmanNon-Executive Director | Nov 2018 |
Mr Lynch-Bell is a corporate finance executive and consultant. His early Ernst & Young career was focused on auditing clients within the oil and gas sectors and later added mining to his portfolio. Michael also led Ernst & Young's UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice. He has been involved advising companies on fundraising, re organisations, transactions, corporate governance as well as IPOs. Michael is a former Chair of the Bureau and current member of UNECE's Expert Group on Resource Management, non-executive Chair of Serabi Gold plc (SRB.L), and Senior Independent Director and Remuneration Committee Chair of Gem Diamonds Limited (LSE:GEMD).
|
Ms Beatriz Vicen Banzo | Non-Executive Director | Jul 2022 |
Ms Banzo has over 30 years working in the European pharmaceutical industry and is experienced and decorated expert in European pharmaceutical regulatory and quality assurance matters. Prior to joining LGP, Beatriz was the Director of Public Affairs (Market Access and Patient Advocacy), Regulatory and Quality Assurance for Bayer Pharmaceuticals and Consumer Health in Spain, Head of Regulatory Affairs and Permanent Executive Committee Guest at Novartis Pharmaceutical Company. Since 2015, Beatriz has also lectured the Masters program at the Madrid based Professional College Talento Farmaceutico and is fluent in four languages.
|
Mr Alistair Warren | Company Secretary | Jul 2020 |
-
|
Paul Long | Chief Executive Officer |
-
|
|
Alistair Warren | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 32,309,383 | 10.71% |
Ubs Nominees Pty Ltd | 32,256,846 | 10.69% |
Ms Fleta Jennifer Solomon | 21,873,216 | 7.25% |
Barbright Australia Pty Ltd <Interquartz Super A/C> | 14,420,420 | 4.78% |
Bnp Paribas Nominees Pty Ltd Acf Clearstream | 7,334,936 | 2.43% |
Mr Angus Caithness | 5,751,441 | 1.91% |
Banquo Consulting Pty Ltd | 5,413,333 | 1.79% |
Finclear Services Pty Ltd <Superhero Securities A/C> | 4,217,543 | 1.40% |
Cg Nominees (Australia) Pty Ltd | 4,147,061 | 1.37% |
Benoni Pty Ltd <The Mkj Super Fund A/C> | 4,082,127 | 1.35% |
Citicorp Nominees Pty Limited | 2,906,193 | 0.96% |
Mr Paul Frederick Long <The Long A/C> | 2,426,191 | 0.80% |
Ms Jenny Lorraine Mckay <J and K Mckay Family A/C> | 2,229,746 | 0.74% |
Mr Damien Matthew Booth <Damien Booth Family A/C> | 1,858,639 | 0.62% |
Mr Michael David Lynch Bell | 1,758,450 | 0.58% |
Jasforce Pty Ltd | 1,705,556 | 0.57% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,557,072 | 0.52% |
Mr Sean Edward Reid and Ms Louise Jane Pilkington | 1,552,600 | 0.51% |
Jensen Jarrah Pty Ltd | 1,369,231 | 0.45% |
Ms Rhianna Louise Belcham | 1,250,000 | 0.41% |